Sania Therapeutics
- Company typePrivate
- Founded2023
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Sania Therapeutics firmographics
Firmographics- Name
- Sania Therapeutics
- Legal name
- Sania Therapeutics Inc.
- Website
- https://saniarx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Sania Therapeutics industry classification
Industry- Product category
- Neurological Gene Therapy
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Sania Therapeutics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Sania Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Distribution channels1 record
Marketing channels5 records
Sania Therapeutics product offering
Product offeringCore offering
Sania Therapeutics develops precision gene therapies for neural circuit dysfunction using a proprietary AAV gene therapy platform. Its offering combines cell-type-specific AAV capsids for targeted gene delivery with a titratable Circuit Control system that activates dormant therapeutic expression via an oral medicine. The pipeline is initially directed at prevalent nervous system disorders such as spasticity, with therapy development conducted through a human-first approach using recreated human neural circuitry.
Product overview
Sania Therapeutics is developing precision gene therapies for neural circuit dysfunction. The company operates a unified therapeutic approach combining two core technology platforms: an AAV Gene Therapy Platform for targeted gene delivery and a Circuit Control System for neuromodulation. Their precision delivery platform utilizes proprietary R-scan and Neu-scan technologies to selectively target neural circuits. The company's human-first approach recreates functional human neural circuits in the lab for therapeutic vector identification, and their controllable therapeutic system allows patients to activate treatment via an oral medicine after receiving an initial injection. The company is initially focused on treating spasticity as a demonstration of their low dose, targeted, and controllable gene therapy approach.
Differentiator
Problem solved
Functional benefit
Products and services
- AAV Gene Therapy Platform Proprietary adeno-associated virus (AAV) gene therapy platform for targeted gene delivery to neural circuits, using human-evolved, cell-type-specific AAV capsids for precision gene therapy. Targeted at developers and researchers advancing treatments for nervous system disorders.
- Circuit Control System Neuromodulation system providing adjustable remote control for selectively altering aberrant neuronal activity. Patients receive an injection of therapy expressed only in targeted neurons, which remains dormant until activated by an oral medicine.
- Precision Delivery Platform Proprietary technology platform that uses a human-first approach to engineer cell-type-specific gene delivery vectors by recreating functional human neural circuits in the lab, enabling efficient identification of therapeutic vectors for precision gene therapy.
Companies that use Sania Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Sania Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Sania Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights5 records
Sania Therapeutics competitors and assessment
Company assessmentDirect peers
- Voyager Therapeutics: Clinical-stage AAV gene therapy company focused on CNS disorders including Parkinson's, Huntington's, and ALS using proprietary capsids. Directly comparable to Sania on modality (AAV), indication area (CNS), and platform (engineered capsids).
- Lexeo Therapeutics: Clinical-stage AAV-based gene therapy developer with a focus on CNS and cardiac indications. Comparable to Sania on AAV delivery platform, central-nervous-system targeting, and pre-commercial development stage.
- Taysha Gene Therapies: Clinical-stage AAV gene therapy company focused on severe monogenic CNS diseases, with a capsid platform from UT Southwestern. Directly comparable to Sania on AAV modality, CNS focus, and pre-clinical/early-clinical pipeline.
Broad incumbents
- Regenxbio: Clinical/commercial AAV gene therapy platform company whose NAV Technology underpins multiple approved and clinical-stage CNS, ophthalmology, and rare-disease gene therapies. Comparable as a broader AAV platform incumbent licensing to multiple partners.
- uniQure: Commercial-stage gene therapy company with AAV-based products for CNS (e.g., Spinraza co-development history, Huntington's program) and hemophilia. Comparable as an established AAV developer operating in similar neurological indications.
- AskBio (Asklepios BioPharmaceutical): AAV gene therapy platform company (acquired by Pfizer) with CNS programs including Parkinson's and Huntington's. Comparable to Sania on AAV capsid engineering focus and CNS indication pipeline, though at much larger scale.
- Pfizer (Gene Therapy / AAV division): Large pharmaceutical with multiple AAV gene therapy programs in CNS and rare disease (e.g., via AskBio acquisition, Beqvez, others). Comparable as a major competitor/partner for AAV CNS programs.
Emerging players
- Capsida Biotherapeutics: Pre-clinical/early-clinical AAV gene therapy company engineering next-generation capsids for CNS and other tissues. Highly comparable to Sania on the engineered-capsid platform thesis and CNS focus, with similar size and stage.
- Solid Biosciences: Clinical-stage gene therapy company focused on Duchenne muscular dystrophy and CNS/cardiometabolic AAV programs. Comparable as a small-cap AAV gene therapy developer with a similar development-stage profile.
- Encoded Therapeutics: Clinical-stage gene therapy company targeting CNS disorders (e.g., Dravet syndrome) using AAV-delivered regulatory elements. Comparable to Sania on CNS indication focus, AAV modality, and pre-commercial development stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Sania Therapeutics social profiles
Digital presenceSania Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sania Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Sania Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Sania Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sania Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sania Therapeutics
What does Sania Therapeutics do?
Sania Therapeutics develops precision gene therapies for neural circuit dysfunction using a proprietary AAV gene therapy platform. Its offering combines cell-type-specific AAV capsids for targeted gene delivery with a titratable Circuit Control system that activates dormant therapeutic expression via an oral medicine. The pipeline is initially directed at prevalent nervous system disorders such as spasticity, with therapy development conducted through a human-first approach using recreated human neural circuitry.
Is Sania Therapeutics a public or private company?
Sania Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sania Therapeutics founded?
Sania Therapeutics was founded in 2023. It employs 11 to 50 people.
Where is Sania Therapeutics based?
Sania Therapeutics is headquartered in London, United Kingdom, in the Europe region.
Who are Sania Therapeutics's main competitors?
Direct peers on record are Voyager Therapeutics, Lexeo Therapeutics and Taysha Gene Therapies. Broad incumbents are Regenxbio, uniQure, AskBio (Asklepios BioPharmaceutical) and Pfizer (Gene Therapy / AAV division). Emerging players are Capsida Biotherapeutics, Solid Biosciences and Encoded Therapeutics.
Does Sania Therapeutics have an API?
No public API is recorded for Sania Therapeutics.
What industry is Sania Therapeutics in?
Sania Therapeutics's product category is Neurological Gene Therapy. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers.